LY 379196
LY 379196 is a PKC-β inhibitor (IC50: 50 nM and 30 nM for PKC βI and βII respectively) . LY 379196 inhibits the VEGF, IGF-1 and bFGF-induced proliferation of bovine retinal microvascular endothelial cells (BREC) . LY 379196 is an antiproliferatory agentfor proliferative retinopathy[1][2].
Product Specifications
UNSPSC
12352005
Target
PKC
Type
Reference compound
Related Pathways
Epigenetics; TGF-beta/Smad
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ly-379196.html
Smiles
O=C1NC(C2=C1C(C3=CC=CC=C34)=CN4CCC[C@H](CN(C)C)CCN5C6=CC=CC=C6C2=C5)=O.O=S(O)(C)=O
Molecular Formula
C30H34N4O5S
Molecular Weight
562.68
References & Citations
[1]Lin WW, et al. Distinct PKC isoforms mediate the activation of cPLA2 and adenylyl cyclase by phorbol ester in RAW264.7 macrophages. Br J Pharmacol. 1998 Dec;125 (7) :1601-9.|[2]G.E. Lang, et al. Effect of the PKC ß Inhibitor LY 379196 in Combination with Growth Factors on Proliferation of Bovine Retinal Vascular Endothelial Cells. ARVO Annual Meeting Abstract. May 2003
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
C7904-43G-ML490 100 µL
COT, CT (Cancer Osaka Thyroid Oncogene, c-COT, EST, ESTF, Mitogen-activated Protein Kinase Kinase Kinase 8, MAP3K8, MEKK8, Proto-oncogene c-Cot, Serine/threonine-protein Kinase Cot, Tumor Progression Locus 2, TPL2, TPL-2) (MaxLight 490) discontinued
Sign In for Pricing
View Details 
